Loading news...
NEW HAVEN, Conn., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) and the SPEAR Study Group today announced the plan to initiate a Phase 2 clinical trial evaluating monoclonal antibody VYD2311 in individuals with Long COVID or COVID vaccine injury.
Invivyd, Inc. (NASDAQ: IVVD - Get Free Report)'s share price shot up 10.6% on Friday. The stock traded as high as $2.72 and last traded at $2.7750. 986,174 shares changed hands during mid-day trading, a decline of 58% from the average session volume of 2,360,294 shares. The stock had previously closed at $2.51. Analysts Set
NEW HAVEN, Conn., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced preliminary fourth quarter (Q4) revenue and recent business highlights.
NEW HAVEN, Conn., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for VYD2311, an investigational vaccine-alternative monoclonal antibody candidate for the prevention of COVID.
NEW HAVEN, Conn., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced initiation of the DECLARATION trial evaluating VYD2311, an investigational vaccine-alternative monoclonal antibody candidate for the prevention of COVID. DECLARATION is the company's Biologics License Application (BLA)-enabling, Phase 3 randomized, triple-blind, placebo-controlled clinical trial to evaluate VYD2311 efficacy and safety in prevention of symptomatic COVID in a broad population of participants including adults and adolescents.
Pre-Market Stock Futures: Futures are trading higher as we get ready to start a holiday-shortened trading week after an outstanding triple-witching Friday rally that may have kicked the "Santa Claus" rally into high gear. All of the major indices, including the Russell 2000, finished the day higher, and Oracle Corp. (NYSE: ORCL), which has been... Here Are Monday's Top Wall Street Analyst Research Calls: BlackSky Technology, Cummins, Lamb Watson, Ollie's Bargain Outlet, Sealed Air, Volaris, and More.
NEW HAVEN, Conn., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that management will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025, at 2:35 p.m. ET in Miami, FL.
NEW HAVEN, Conn., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced it has identified and nominated for preclinical development a potentially best-in-class monoclonal antibody candidate for the prevention of Respiratory Syncytial Virus (RSV) among neonates, infants, and children. Invivyd's investigational antibody, VBY329, was generated by Invivyd's proprietary antibody discovery technology, targeted at high value infectious diseases. RSV is a common respiratory illness and is the leading cause of hospitalization for infants in the United States.
Invivyd, Inc. remains a Hold rating as it advances its monoclonal antibody pipeline, notably VYD2311 as a Covid-19 vaccine alternative. VYD2311 offers broader patient coverage and intramuscular dosing, with phase 3 DECLARATION and LIBERTY trials set to begin by end of 2025; Topline data mid-2026. Company's technology shows strong variant-neutralization, and expansion into RSV and measles prevention could unlock other market opportunities.
U.S. stock futures were lower this morning, with the Dow futures falling around 200 points on Tuesday.
NEW HAVEN, Conn., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Invivyd) (Nasdaq: IVVD) today announced the pricing of an underwritten public offering of 44,000,000 shares of its common stock at an offering price of $2.50 per share and, to certain investors, in lieu of common stock, pre-funded warrants to purchase 6,000,000 shares of its common stock at a price of $2.4999 per pre-funded warrant. The gross proceeds from this offering are expected to be approximately $125.0 million, before deducting underwriting discounts and commissions and offering expenses payable by Invivyd. The purchase price per share of each pre-funded warrant represents the per share offering price for the common stock, minus the $0.0001 per share exercise price of each such pre-funded warrant. All of the shares and pre-funded warrants are being offered by Invivyd. In addition, Invivyd has granted the underwriters an option for a period of 30 days to purchase up to an additional 7,500,000 shares of Invivyd common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about November 19, 2025, subject to the satisfaction of customary closing conditions.
NEW HAVEN, Conn., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Invivyd) (Nasdaq: IVVD) today announced that it has commenced an underwritten public offering of shares of its common stock. In addition, Invivyd intends to grant the underwriters an option for a period of 30 days to purchase up to an additional 15% of the shares of Invivyd common stock sold in the public offering at the public offering price, less underwriting discounts and commissions. All of the shares are being offered by Invivyd. The offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Invivyd, Inc. (NASDAQ: IVVD - Get Free Report) hit a new 52-week high during mid-day trading on Saturday. The stock traded as high as $2.76 and last traded at $2.35, with a volume of 136241658 shares trading hands. The stock had previously closed at $1.77. Analysts Set New Price Targets Several brokerages recently weighed in
Invivyd, Inc. (NASDAQ: IVVD - Get Free Report) was the recipient of some unusual options trading activity on Friday. Stock investors purchased 2,953 call options on the company. This is an increase of approximately 283% compared to the average daily volume of 771 call options. Analyst Ratings Changes A number of brokerages have recently issued reports
Invivyd, Inc. ( IVVD ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants Katie Falzone Marc Elia Timothy Lee - Chief Commercial Officer William Duke - CFO, Principal Accounting Officer & Principal Executive Officer Conference Call Participants Joshua Schimmer - Cantor Fitzgerald & Co., Research Division Patrick Trucchio - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good morning, everyone, and welcome to the Q3 2025 Invivyd Earnings Conference Call.
Invivyd, Inc. (IVVD) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to a loss of $0.51 per share a year ago.
NEW HAVEN, Conn., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced financial results for the quarter ended September 30, 2025, and provided recent business highlights.
NEW HAVEN, Conn., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company focused on delivering protection from serious viral infectious diseases, today announced that it will host a conference call on Thursday, November 6, 2025, at 8:30 a.m. ET to discuss its third quarter 2025 financial results and provide a corporate update.
Invivyd, Inc. ( IVVD ) Discusses REVOLUTION Clinical Program and Development of VYD2311 Antibody for COVID Prevention October 30, 2025 8:30 AM EDT Company Participants Katie Falzone Marc Elia Robert Allen - Chief Scientific Officer Mark Wingertzahn - Senior Vice President of Clinical Development & Medical Affairs Timothy Lee - Chief Commercial Officer Conference Call Participants Joshua Schimmer - Cantor Fitzgerald & Co., Research Division Patrick Trucchio - H.C. Wainwright & Co, LLC, Research Division Thomas Shrader - BTIG, LLC, Research Division Presentation Operator Good day and thank you for standing by.
NEW HAVEN, Conn., Oct. 28, 2025 (GLOBE NEWSWIRE) -- WHAT: Invivyd, Inc. (Nasdaq: IVVD) is hosting the previously announced live webcast to present an overview of the company's REVOLUTION clinical program, Invivyd's development program for VYD2311, a vaccine-alternative monoclonal antibody candidate for the prevention of COVID. The session will feature key members of the Invivyd team.